SynthesisFrontiers in oncology2026
Monocyte-to-lymphocyte ratio as a predictor of outcomes in patients with hepatocellular carcinoma.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The monocyte-to-lymphocyte ratio(MLR) as an immune indicator has been found to be associated with the prognosis of various tumors. This study aimed to determine prognostic value of MLR in patients with hepatocellular carcinoma (HCC) by the meta-analysis. Methods: A comprehensive literature search was conducted in PubMed, Web of Science, and Embase up to July 25, 2025. Survival outcome included overall survival (OS), recurrence free survival (RFS), progression-free survival (PFS), and disease-free survival (DFS) were analyzed. Results: A total of 17 studies comprising 7113 patients were included in the meta-analysis. The pooled results displayed that high MLR was significantly associated with poor OS (HR:1.57,95% CI:1.22-2.02), RFS(HR:2.40,95%CI:1.73-3.33) and PFS(HR:2.04,95%CI:1.57-2.65).However, high MLR was not associated with DFS(HR:1.01,95%CI:0.86-1.18). The prognostic relevance of MLR in HCC was consistently demonstrated across subgroup analyses. Conclusion: High MLR was associated with poor prognosis in patients with HCC. MLR may be a valuable and non-invasive prognostic indicator for HCC patients in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.